Developing novel strategies for targeted drug delivery

Delivering therapeutic payload to specific target cells, thus increasing the efficiency and reducing adverse effects, is considered by many to be the holy grail of medical research. We designed a self-assembled modular platform named ASSET, Anchored Secondary scFv Enabling Targeting, to facilitate the construction of a theoretically unlimited repertoire of targeted carriers. By utilizing a biological approach for conjugation of monoclonal antibodies(mAbs), we were able to overcome the limitations of current methodologies. ASSET is based on a lipoprotein, self-assembles into the membrane of the LNPs and interacts with the mAbs’ Fc domain. With a simple switch of different mAbs, it redirects specific uptake of RNAs by diverse subsets.

  1. Veiga N, et al(2019) Leukocyte-Specific siRNA Delivery Revealing IRF8 as a Potential Anti-Inflammatory Target. J Control Release.  313:33-41. PDF
  2. Veiga N, et al (2018) Cell-specific delivery of modified mRNA expressing therapeutic proteins to leukocytes. Nat Commun. 9(1):4493-449. PDF
  3. Kedmi R, et al (2018) A modular platform for targeted RNAi therapeutics. Nature Nanotechnology. PDF 13(3):214-219.